The impact of the secondary infections in ICU patients affected by COVID-19 during three different phases of the SARS-CoV-2 pandemic.
Blood chemistry parameters
COVID-19
Clinical outcome
Microbiological data
SARS-COV-2 infection
Secondary infections
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
30
09
2022
accepted:
18
11
2022
medline:
1
8
2023
pubmed:
3
12
2022
entrez:
2
12
2022
Statut:
ppublish
Résumé
Microbial secondary infections can contribute to an increase in the risk of mortality in COVID-19 patients, particularly in case of severe diseases. In this study, we collected and evaluated the clinical, laboratory and microbiological data of COVID-19 critical ill patients requiring intensive care (ICU) to evaluate the significance and the prognostic value of these parameters. One hundred seventy-eight ICU patients with severe COVID-19, hospitalized at the S. Francesco Hospital of Nuoro (Italy) in the period from March 2020 to May 2021, were enrolled in this study. Clinical data and microbiological results were collected. Blood chemistry parameters, relative to three different time points, were analyzed through multivariate and univariate statistical approaches. Seventy-four percent of the ICU COVID-19 patients had a negative outcome, while 26% had a favorable prognosis. A correlation between the laboratory parameters and days of hospitalization of the patients was observed with significant differences between the two groups. Moreover, Staphylococcus aureus, Enterococcus faecalis, Candida spp, Pseudomonas aeruginosa and Klebsiella pneumoniae were the most frequently isolated microorganisms from all clinical specimens. Secondary infections play an important role in the clinical outcome. The analysis of the blood chemistry tests was found useful in monitoring the progression of COVID-19.
Identifiants
pubmed: 36459278
doi: 10.1007/s10238-022-00959-1
pii: 10.1007/s10238-022-00959-1
pmc: PMC9717567
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1251-1263Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet. 2020;395:470–3.
doi: 10.1016/S0140-6736(20)30185-9
pubmed: 31986257
Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a global health crisis. Physiol Genomics. 2020;52:549–57.
doi: 10.1152/physiolgenomics.00089.2020
pubmed: 32991251
Parohan M, Yaghoubi S, Seraji A, et al. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male. 2020;23:1416–24.
doi: 10.1080/13685538.2020.1774748
pubmed: 32508193
McArdle AJ, Turkova A, Cunnington AJ. When do co-infections matter? Curr Opin Infect Dis. 2018;31:209–15.
doi: 10.1097/QCO.0000000000000447
pubmed: 29698255
Mirzaei R, Goodarzi P, Asadi M, et al. Bacterial co-infections with SARS-CoV-2. IUBMB Life. 2020;72:2097–111.
doi: 10.1002/iub.2356
pubmed: 32770825
Jia L, Xie J, Zhao J, et al. Mechanisms of severe mortality-associated bacterial co-infections following influenza virus infection. Front Cell Infect Microbiol. 2017;7:338.
doi: 10.3389/fcimb.2017.00338
pubmed: 28824877
Quah J, Jiang B, Tan PC, et al. Impact of microbial Aetiology on mortality in severe community-acquired pneumonia. BMC Infect Dis. 2018;18:451.
doi: 10.1186/s12879-018-3366-4
pubmed: 30180811
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395:497–506.
doi: 10.1016/S0140-6736(20)30183-5
pubmed: 31986264
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.
doi: 10.1016/S0140-6736(20)30566-3
pubmed: 32171076
Zhang G, Hu C, Luo L, et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan. China J Clin Virol. 2020;127: 104364.
doi: 10.1016/j.jcv.2020.104364
pubmed: 32311650
Hendaus MA, Jomha FA. Covid-19 induced superimposed bacterial infection. J Biomol Struct Dyn. 2021;39:4185–91.
doi: 10.1080/07391102.2020.1772110
pubmed: 32448041
Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. Clin Microbiol Infect. 2021;27:9–11.
doi: 10.1016/j.cmi.2020.09.025
pubmed: 32979569
Ritchie AI, Singanayagam A. Immunosuppression for hyper inflammation in COVID-19: a double-edged sword? Lancet. 2020;395:1111.
doi: 10.1016/S0140-6736(20)30691-7
pubmed: 32220278
Blasco ML, Buesa J, Colomina J, et al. Co-detection of respiratory pathogens in patients hospitalized with Coronavirus viral disease-2019 pneumonia. J Med Virol. 2020;92:1799–801.
doi: 10.1002/jmv.25922
pubmed: 32320082
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.
doi: 10.1016/S0140-6736(20)30211-7
pubmed: 32007143
Cox MJ, Loman N, Bogaert D, et al. Co-infections: potentially lethal and unexplored in COVID-19. Lancet Microbe. 2020;1(1): e11.
doi: 10.1016/S2666-5247(20)30009-4
pubmed: 32835323
Costa VO, Nicolini EM, da Costa BMA, et al. Evaluation of the Risk of Clinical Deterioration among Inpatients with COVID-19. Adv Virol. 2021;2021:6689669.
doi: 10.1155/2021/6689669
pubmed: 34257657
Murgia F, Fiamma M, Serra S, et al. The impact of secondary infections in COVID-19 critically ill patients. J Infect. 2022;84(6):e116–7.
doi: 10.1016/j.jinf.2022.03.017
pubmed: 35314266
Eriksson L, Byrne T, Johansson E, et al. Multi- and megavariate data analysis basic principles and applications. Umetrics Academy; 2013. 509.
Wold S, Sjöström M, Eriksson L. PLS-regression: a basic tool of chemometrics. Chemom Intell Lab Syst. 2001;58:109–30.
doi: 10.1016/S0169-7439(01)00155-1
Lindgren F, Hansen B, Karcher W, et al. Model validation by permutation tests: applications to variable selection. J Chemom. 1996;10:521–32.
doi: 10.1002/(SICI)1099-128X(199609)10:5/6<521::AID-CEM448>3.0.CO;2-J
Wang P, Lu J-A, Jin Y, et al. Statistical and network analysis of 1212 COVID-19 patients in Henan. China Int J Infect Dis. 2020;95:391–8.
doi: 10.1016/j.ijid.2020.04.051
pubmed: 32339715
Zhao Y, Zhao Z, Wang Y, et al. Single-Cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020;202:756–9.
doi: 10.1164/rccm.202001-0179LE
pubmed: 32663409
Kashyap VK, Dhasmana A, Massey A, et al. Smoking and COVID-19: adding fuel to the flame. Int J Mol Sci. 2020;21:E6581.
doi: 10.3390/ijms21186581
Ejaz H, Alsrhani A, Zafar A, et al. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 2020;13:1833–9.
doi: 10.1016/j.jiph.2020.07.014
pubmed: 32788073
Parohan M, Yaghoubi S, Seraji A, et al. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male. 2020;23:1416–24.
doi: 10.1080/13685538.2020.1774748
pubmed: 32508193
Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: a meta-analysis. Cytometry A. 2020;97:772–6.
doi: 10.1002/cyto.a.24172
pubmed: 32542842
Kermali M, Khalsa RK, Pillai K, et al. The role of biomarkers in diagnosis of COVID-19 - a systematic review. Life Sci. 2020;254: 117788.
doi: 10.1016/j.lfs.2020.117788
pubmed: 32475810
Garcia-Vidal C, Sanjuan G, Moreno-García E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27:83–8.
doi: 10.1016/j.cmi.2020.07.041
pubmed: 32745596
Kubin CJ, McConville TH, Dietz D, et al. Characterization of bacterial and fungal infections in hospitalized patients with coronavirus disease 2019 and factors associated with health care-associated infections. Open Forum Infect Dis. 2021;8(6):ofab201.
doi: 10.1093/ofid/ofab201
pubmed: 34099978
Huang ACC, Huang CG, Yang CT, et al. Concomitant infection with COVID-19 and Mycoplasma pneumoniae. Biomed J. 2020;43(5):458–61.
doi: 10.1016/j.bj.2020.07.002
pubmed: 32891590
Ghoneim HE, Thomas PG, McCullers JA. Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. J Immunol. 2013;191(3):1250–9.
doi: 10.4049/jimmunol.1300014
pubmed: 23804714
Zhang H, Zhang Y, Wu J, et al. Risks and features of secondary infections in severe and critical ill COVID-19 patients. Emerg Microbes Infect. 2020;9(1):1958–64.
doi: 10.1080/22221751.2020.1812437
pubmed: 32815458
Zangrillo A, Beretta L, Scandroglio AM, et al. Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan. Italy Crit Care Resusc. 2020;22(3):200–11.
pubmed: 32900326
Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, et al. Azithromycin in the treatment of COVID-19: a review. Expert Rev Anti Infect Ther. 2021;19(2):147–63.
doi: 10.1080/14787210.2020.1813024
pubmed: 32853038